Judge pares claims in Bard IVC bellwether
A federal judge in Arizona yesterday pared some claims in the third bellwether case involving inferior vena cava filters made by Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard, as the trial entered its 11th day. It’s the fourth bellwether in the multi-district litigation over the IVC devices, which are designed to prevent blood clots from passing through the body’s largest vein into the heart and lungs. In the first case to go to trial, a federal jury in Phoenix found for plaintiff Sherr-Una Booker, awarding $3.6 million in damages. Bard prevailed in the second bellwether trial, with the jury findin...
Source: Mass Device - October 3, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Legal News Product Liability Vascular bectondickinson crbard Source Type: news
InfoBionic drums up $50m for MoMe Kardia remote heart monitor
InfoBionic said today that it raised another $50 million for its wireless remote cardiac monitor. Boston-based InfoBionic said Eagle Investments, Excel Venture Management, Safeguard Scientifics, Blue Cross Blue Shield of Massachusetts subsidiary Zaffre Investments and Blue Cross and Blue Shield of Kansas all participated in the round. The company sells the MoMe Kardia device, a remote, wireless outpatient system for monitoring & diagnosis of cardiac arrhythmias. It won 510(k) clearance from the FDA in 2015. Last month, InfoBionic inked a deal giving exclusive U.S. distribution rights for the MoMe Kardia syste...
Source: Mass Device - September 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Funding Roundup Patient Monitoring Wall Street Beat InfoBionic Source Type: news
Biotronik Enters into Distribution Agreement with InfoBionics
Biotronik has become the exclusive US distributor for InfoBionic's MoMe Kardia external cardiac diagnostic monitor. The device benefits patients suspected of experiencing cardiac arrhythmias. âWhen weâre looking at partners -Â weâre asking ourselves -Â are these partners able to do the three main things that are important to us,â Rupa Basu, Senior Vice President of Marketing, Corporate Accounts and Strategy, at Biotronik, told MD+DI. âThe first thing is, is it going to improve the patientâs expe...
Source: MDDI - September 7, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news
Biotronik to distribute InfoBionic monitor in U.S.
Biotronik has landed exclusive U.S. distributorship for InfoBionic’s MoMe Kardia external cardiac diagnostic monitor. MoMe Kardia was designed to increase early detection and diagnosis of cardiac arrhythmias by providing physicians with the ability to access near real-time electrocardiographic data. Monitoring can also uncover patients at higher risk of sudden cardiac death. Get the full story on our sister site, Medical Design & Outsourcing. The post Biotronik to distribute InfoBionic monitor in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 28, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Cardiac Assist Devices Distribution Biotronik InfoBionic Source Type: news
Bankers in their twenties suffering more heart attacks, doctors warn
These unlikely patients regularly present themselves with two types of heart conditions: cardiac arrhythmia and myocarditis. (Source: the Mail online | Health)
Source: the Mail online | Health - August 6, 2018 Category: Consumer Health News Source Type: news
The future of Abbott ’ s electrophysiology business
At DeviceTalks Minnesota 2018, medtech veteran Michael Pederson provided an inside look at the Abbott-St. Jude Medical merger and what’s ahead for Abbott’s cardiovascular technologies. Pederson tracked his career from a formative stint at HP to his current role as SVP of cardiac arrhythmias and heart failure at Abbott (NYSE:ABT). Check out his keynote address with DeviceTalks founder Brian Johnson. To learn more from the brightest minds in medtech, don’t miss DeviceTalks Boston on Oct. 8-10 The post The future of Abbott’s electrophysiology business appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Cardiovascular DeviceTalks Q&A Wall Street Beat Abbott DeviceTalks Boston DeviceTalks Minnesota Source Type: news
Johnson & Johnson hits the Big Apple with latest JLabs site
Johnson & Johnson (NYSE:JNJ) opened its latest life science incubator in New York City, the healthcare giant said today. The 30,000-square-foot JLabs @ NYC is a collaboration between Johnson & Johnson Innovation, New York State and the New York Genome Center. Sited at the genome center in SoHo, the incubator is home to 26 startups and has room for four more, New Brunswick, N.J.-based J&J said. “Johnson & Johnson has deep entrepreneurial roots in New York and we are pleased to see our unique JLabs model applied in this rich ecosystem to foster the creation of new healthcare innovations that have t...
Source: Mass Device - June 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Research & Development johnsonandjohnson Source Type: news
Philips acquires Remote Diagnostic Technologies
Royal Philips (NYSE:PHG) said today it acquired U.K.-based Remote Diagnostic Technologies for an undisclosed amount. Remote Diagnostic Technologies develops cardiac therapy, data management and monitoring solutions for the pre-hospital market, and has a portfolio of connected emergency care solutions that Amsterdam-based Philips said will complement its therapeutic care biz. “We are committed to investing in and expanding our resuscitation and emergency care offering, and with the acquisition of RDT we can boost our capabilities and portfolio in this vital area of healthcare. With its focus on the pre-hospi...
Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Patient Monitoring royalphilips Source Type: news
Philips to acquire EPD solutions in $293m upfront deal
Royal Philips (NYSE:PHG) said today it inked a deal to acquire image-guided cardiac arrhythmia treatment dev EPD Solutions for $293 million (EU €250 million) upfront with a possible additional $246.2 million (EU €210 million) upon completion of the deal based on certain milestones. EPD Solutions produces cardiac imaging and navigation systems designed to aid electrophysiologists in navigating the heart through a detailed 3D image of the cardiac anatomy, Amsterdam-based Philips said. The system is also designed to identify the location and orientation of catheters during the diagnostic and therapeutic pr...
Source: Mass Device - June 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Mergers & Acquisitions royalphilips Source Type: news
Philips Bets Big on Image-Guided Therapy with Latest Acquisition
Royal Philips is seeking to expand its image-guided therapy solutions with the acquisition EPD Solutions. Philips is set to acquire the Tortola, British Virgin Islands-based company for about $292 million upfront. The deal could close in July, Philips said. EPD’s cardiac imaging and navigation system has received CE mark and is used in diagnostic and therapeutic procedures for cardiac arrhythmias. The system has not been given a nod from FDA and is currently under review by the agency. Philips said its interventional imaging systems, such as Azurion, and EPD’s cardiac imaging and navigation system could more ef...
Source: MDDI - June 5, 2018 Category: Medical Devices Authors: Omar Ford Tags: Imaging Cardiovascular Source Type: news
Boston Scientific touts safety, effectiveness in Rhythmia mapping study
Boston Scientific‘s (NYSE:BSX) Rhythmia mapping system and catheter was found to be safe and effective in procedures to treat arrhythmias, according to a Healio summary of a newly released study from the company. Researchers in the study examined 572 patients, with 519 patients undergoing procedures with the Rhythmia system and IntellaMap Orion catheter, according to the report. A total of 504 patients had a complete mapping procedure and were followed for one month post-procedure. Findings from the study were presented at the EHRA 2018 meeting, according to Healio. The primary endpoint of the trial was acute procedu...
Source: Mass Device - May 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Imaging Boston Scientific Source Type: news
New Cardiac Mapping Options for Complex Arrhythmias
CARLSBAD, Calif., May 8, 2018 /PRNewswire/ -- Acutus Medical®, a global heart rhythm technology company, today announced that the AcQMap® High Resolution Imaging and Mapping System has been utilized for the first time in U.S. patients. The company also revealed initiation of a new clinical study to evaluate the technology during atrial fibrillation retreatment ablation procedures in Europe and Canada. "Enabling physicians to see complex, irregular arrhythmias in real-time should provide important new insights and enable truly personalized and individualized abla...
Source: MDDI - May 9, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Imaging Source Type: news
Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
ADVISOR HD GRID MAPPING CATHETER, SENSOR ENABLED FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS FIRST-OF-ITS-KIND GRID CONFIGURATION IS DESIGNED TO CAPTURE DATA IN MULTIPLE DIRECTIONS T... Devices, Cardiology, FDA Abbott, Advisor, HD Grid Mapping Catheter, Arrhythmia, electrophysiology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 3, 2018 Category: Pharmaceuticals Source Type: news
For this Abbott executive, solving problems isn ’ t enough: ‘ We need to add value ’
As payers and providers across healthcare shift their focus to value-based care, leaders in the medical device industry are racing to keep up. Michael Pederson, SVP of cardiac arrhythmias and heart failure at Abbott, told MassDevice.com why simply solving problems with new technology isn’t enough anymore. What was your path like from electrical engineering to Abbott’s cardiac arrhythmia business? Pederson: As an engineer, I’ve always been drawn to how technology can evolve and re-shape entire industries. In particular, health technology can fundamentally change the lives of people battling complex health ...
Source: Mass Device - May 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Wall Street Beat Abbott devicetalksminnesota Source Type: news
Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
- ADVISOR ™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS (Source: Abbott.com)
Source: Abbott.com - May 3, 2018 Category: Pharmaceuticals Source Type: news
Concerns Over Tick, Mosquito-Borne Diseases Rise After CDC Report
BOSTON (CBS) — A Center for Disease Control and Prevention (C.D.C.) report is raising concerns. From 2004-2016 the amount of tick, mosquito, and flea-transmitted diseases have tripled in the U.S. Nearly 60% of the diseases detected came from ticks. Dr. David Crandell, clinical co-director for the Dean Center Tick-Borne Illness at Spaulding Rehabilitation Hospital, says he’s not surprised. Dr. Crandell believes an increase in Lyme disease diagnosis comes from better testing and more importantly, a better understanding of the disease and the signs. He says symptoms include: Malaise, almost like a flu-like symptom...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 2, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Seen On WBZ-TV Syndicated Local CDC Gary Brode Local TV Mosquitoes tick-borne disease ticks Source Type: news
Substance in Chinese medicine can cause cardiac arrhythmia
(University of Basel) A medicinal plant frequently used in Traditional Chinese Medicine (TCM) -- Evodia rutaecarpa -- contains substances that can cause cardiac arrhythmia. This is what researchers from the Universities of Basel, Vienna and Utrecht have recently found out. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 2, 2018 Category: Biology Source Type: news
Reconstructing what makes us tick
(American Institute of Physics) A major issue that limits modeling to predict cardiac arrhythmia is that it is impossible to measure and monitor all the variables that make our hearts tick, but researchers have now developed an algorithm that uses artificial intelligence to model the electrical excitations in heart muscle. Their work, appearing in Chaos, draws on partial differential equations describing excitable media and echo state networks to cross-predict variables about chaotic electrical wave propagations in cardiac tissue. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2018 Category: International Medicine & Public Health Source Type: news
Coffee, Tea Not Necessarily Hazard to Heart Rhythm (CME/CE)
(MedPage Today) -- But cardiac arrhythmia patients should steer clear of energy drinks (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 17, 2018 Category: Primary Care Source Type: news
Cardiva Medical adds $11m for vascular closure devices
Cardiva Medical said yesterday that it added another $11 million to a funding round it closed last year at $30 million to continue the commercialization of its Vascade vascular closure device. Existing debt and equity investors participated, including PTV Healthcare Capital, Canepa Healthcare and affiliates of Luther King Capital Mgmt., the Santa Clara, Calif.-based company said. In March 2017 Cardiva said it had put a bow around the $30 million round for Vascade, which won 510(k) clearance from the FDA in February 2013. Yesterday the company said the latest infusion will also go toward its Ambulate investigation...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Vascular Wall Street Beat Cardiva Medical Inc. Source Type: news
High blood pressure - these vitamin supplements will lower your risk of heart attacks
Vitamin D supplements could help to reverse damage to blood vessels after suffering from high blood pressure, scientists have revealed. Cardiovascular damage increases the risk of deadly cardiac arrhythmia. (Source: Daily Express - Health)
Source: Daily Express - Health - January 31, 2018 Category: Consumer Health News Source Type: news
Philips joins $9m round for remote-care co LindaCare
Digital health company LindaCare has landed an $8.7 million Series B round, with investments made by Philips (NYSE:PHG), PMV, Capricorn ICT Arkiv, Connecticut Innovations and others. The Belgium-based company said it plans to use the newly-acquired funds to accelerate its U.S. market expansion and product commercialization, as well as build out its existing patient monitoring software platform for a broader range of cardiac diseases. “This investment is a significant step for us, as it enables LindaCare to execute faster on our ambitious vision and strategy, and to take a leading market position across both...
Source: Mass Device - January 24, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Funding Roundup Patient Monitoring lindacare royalphilips Source Type: news
Cyclizine is sold in Denmark as an over-the-counter drug and has serious side effects when overdosed - Petersen K, Hjorth P.
Cyclizine is sold in Denmark as an over-the-counter drug and affects not only histaminergic but also muscarinergic, serotonergic and α-adrenergic receptors, with side effects such as respiratory depression and cardiac arrhythmias, leading to fatalities. D... (Source: SafetyLit)
Source: SafetyLit - January 18, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
The Startup Caf é, the Place where Healthcare IT Decision-Makers and New Companies can Meet
17 - 19 April 2018, Berlin, Germany. Whether they develop apps that detect the early stages of cardiac arrhythmia or cybersecurity software for hospitals, startups in the healthcare IT sector are flexible, highly innovative and can make a significant contribution to digitalising the healthcare system. (Source: eHealth News EU)
Source: eHealth News EU - January 16, 2018 Category: Information Technology Tags: Featured Events Conferences and Events Source Type: news
Abbott Expands Portfolio of MRI-Ready Devices
FDA gave MR-conditional labeling to two of Abbott's cardiac rhythm management (CRM) devices, a move that further boosts the company's ability to compete with its peers in the space. The Abbott Park, IL-based firm said patients who receive a Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) or a Fortify Assura implantable cardioverter defibrillator (ICD) are now able to have an MRI in the future if need be. The Quadra Assura and the Fortify Assura are two of Abbott's most widely-used high voltage devices, the company noted. In September 2016, Abbott won FDA approval for MR-conditional labeling for the...
Source: MDDI - January 3, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Regulatory and Compliance Source Type: news
The 8th Annual Alexander Awards: The Best Tox Reading of 2017
Alexander Gettler Once again, last year’s outstanding examples of long-form journalism dealing with topics related to medical toxicology were dominated by coverage of the opioid crisis, its origins and the resulting carnage. The must-read article of the year was “The Family That Built a Empire of Pain,” Patrick Radden Keefe’s massive history of the Sacklers, one of America’s richest clans, much of whose wealth comes from their ownership of Purdue Pharma and the marketing and distribution of Oxycontin. The article, which appeared in the New Yorker, notes that the clan’s patriarch, Ar...
Source: The Poison Review - January 2, 2018 Category: Toxicology Authors: Leon Gussow Tags: Medical 2017 Alexander awards opioids Purdue Pharma Sackler Source Type: news
Researchers are developing light therapy as a non-invasive, alternative treatment for disease
(Natural News) Artificial light has both its risks and benefits, but a new study shows that it may be the solution to minimally invasive, drug-free treatments. Researchers are currently developing new ways using infrared neuromodulation to treat cardiac arrhythmia (irregular heart beat), hypertension (high blood pressure), asthma, sleep apnea (suspension of breathing during sleep), diarrhea, and... (Source: NaturalNews.com)
Source: NaturalNews.com - December 18, 2017 Category: Consumer Health News Source Type: news
Spinal Elements lifts former COO Blain to the corner office | Personnel Moves November 30, 2017
Spinal Elements, previously known as Amendia, said this week it is lifting co-founder and current prez & COO Jason Blain to the position of prez & CEO, effective immediately. Prior to coming on to co-found Spinal Elements, Blain served in various roles with medtech companies Smith & Nephew (NYSE:SNN), Alphatec (NSDQ:ATEC) and NuVasive Inc. (NSDQ:NUVA). Blain is replacing Chris Fair, who will stay on as a board member with the company. “I am excited by the opportunity to lead our talented team of employees and partners and create an even more vibrant and dynamic Spinal Elements in the years ...
Source: Mass Device - November 30, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Abbott Alphatec Apica Cardiovascular Bovie Medical Corp. Cardiovascular Systems Inc. Dentsply Sirona Guidant Corp. Lima Corporate Medical Device Innovation Consortium MedLumics MedTech Europe Medtronic Nuv Source Type: news
Shining a light on the nervous system to thwart disease
(Case Western Reserve University) Researchers from Case Western Reserve University School of Medicine, Vanderbilt University, and University of Pittsburgh have received a four-year, $9 million grant from the National Institutes of Health to develop enhanced infrared light technology (infrared neuromodulation) for potentially treating a variety of diseases, including cardiac arrhythmias, high and low blood pressure, asthma, sleep apnea and diarrhea, one of the leading killers of children worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news
URMC Cardiologist Receives High Honor from American Heart Association
University of Rochester Medical Center cardiologist Arthur J. Moss, M.D., whose research on cardiac arrhythmias has saved countless lives and changed the treatment of heart disease worldwide, was honored with the 2017 James B. Herrick Award at the American Heart Association ’s Scientific Sessions. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 13, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Abbott Launches the First and Only Smartphone Compatible Insertable Cardiac Monitor in the U.S.
THE CONFIRM RX ICM COMBINES ADVANCED MEDICAL DEVICE WITH THE LATEST IN MOBILE AND DIGITAL TECHNOLOGY PHYSICIANS CAN REMOTELY MONITOR THEIR PATIENTS WITH CONFIRM RX FOR EVEN THE MOST DIFFICULT TO DETECT CARDIAC ARRHYTHMIAS, INCLUDING IRREGULAR HEARTBEATS... Devices, Monitoring, Cardiology, FDA, Product Launch Abbott, Confirm Rx, Insertable Cardiac Monitor, Cardiac Monitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 23, 2017 Category: Pharmaceuticals Source Type: news
Abbott wins FDA nod for Confirm Rx smartphone-connected cardiac monitor
Abbott (NYSE:ABT) said today it won FDA clearance for its Confirm Rx insertable cardiac monitor, touting it as the 1st and only smartphone compatible ICM designed to help identify cardiac arrhythmias. The Confirm Rx system includes a sensor designed to be implanted just under the skin over the chest in a minimally-invasive outpatient procedure, the company said. The newly cleared device features incorporated Bluetooth wireless technology to allow patients to connect to the device on their smartphone devices through Abbott’s myMerlin mobile application. Data collected by the device is also transmitted to the...
Source: Mass Device - October 23, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Food & Drug Administration (FDA) Patient Monitoring Regulatory/Compliance Abbott Source Type: news
Getting to the heart of mapping arrhythmia-related excitations
(American Institute of Physics) Atrial fibrillation is the most prevalent form of cardiac arrhythmia, affecting up to 6 million people in the US alone. Common treatments for severe forms of the erratic beating phenomenon are controversial, and guided by detection methods that are not yet standardized or fully refined. But research from a group of cross-disciplinary scientists, published this week in the journal Chaos, offers a computational approach to understanding the important factors involved in measuring cardiac excitation waves. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2017 Category: International Medicine & Public Health Source Type: news
Abbott Catches Up to Peers With MRI-Compatible ICD
Abbott Laboratories acquired St. Jude Medical earlier this year knowing that the company trailed behind its peers in the cardiac rhythm management (CRM) space by not having a MRI-compatible pacemaker or implantable cardioverter defibrillator (ICD) system. It seems Abbott has officially caught up in that category though, first with FDA approval of the Assurity MRI pacemaker and the Tendril MRI pacing lead during the first quarter, and now with FDA approval of MRI-conditional labeling for the Ellipse ICD system. Abbott said the recent approval covers one of its most widely-used ICD systems and associated high voltage leads. ...
Source: MDDI - September 23, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: MD & M Minneapolis Labeling Business Source Type: news
Abbott wins MR-conditional label for Ellipse ICDs
Abbott (NYSE:ABT) said today that it won an MR-conditional label from the FDA for the Ellipse implantable cardioverter defibrillator it acquired along with St. Jude Medical early this year. The MR-conditional label applies to Ellipse and the Tendril MRI pacing lead and the Durata and Optisure high-voltage leads, the Chicago-area medical device giant said. “When you consider the number of patients each year who rely on the lifesaving treatment delivered by an ICD device, it is critical to continually innovate to provide new benefits to people battling complex arrhythmias and other cardiac conditions,” cardiac ar...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Food & Drug Administration (FDA) Imaging Regulatory/Compliance Abbott Cardiac Rhythm Management Source Type: news
Is BioSig for Real This Time With Its Pure EP?
A couple years ago, BioSig Technologies, Inc. was poised to apply for FDA clearance to market its technology to improve treatment of atrial fibrillation and ventricular tachycardia. Then its scientific advisors advised the Minneapolis company to put more work into that technology, a hardware-software combination designed to present clearer signals during electrophysiology studies and catheter ablation. The technology, Pure EP, is designed to cut through the background noise of the lab and its equipment during cardiac recordings, enabling physicians to target and neutralize the areas of the heart that are causing atria...
Source: MDDI - September 7, 2017 Category: Medical Devices Authors: Nancy Crotti Tags: MD & M Minneapolis R Software Source Type: news
Abbott wins FDA nod for HeartMate 3 pump
Abbott (NYSE:ABT) said today that the FDA approved its HeartMate 3 implantable pump for heart failure patients awaiting a transplant. The approval is the latest for the HeartMate line of left ventricular assist devices first developed by Thoratec, which was later acquired by St. Jude Medical before a $25 billion merger brought it to Abbott earlier this year. Abbott said HeartMate 3 features full magnetic levitation for the pump’s impeller, aiming to cause less trauma to blood cells as they pass through the pump. Although it is smaller than its predecessor, Abbott claimed it has the industry’s largest ...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Food & Drug Administration (FDA) Abbott Source Type: news
Numerate receives NIH funding to discover new anti-arrhythmic treatments
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded a small business innovation research (SBIR) Phase I grant to Numerate to boost a new drug programme for cardiac arrhythmias. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news
Not all astrocytes in the brain are the same, study finds
From afar, the billions of stars in our galaxy look indistinguishable, just as the billions of star-shaped astrocytes in our brains appear the same as each other. But UCLA researchers have now revealed that astrocytes, a type of brain cell that supports and protects neurons, aren ’t all the same. While stars might be categorized by their size, age and heat, the supportive brain cells vary when it comes to shape, molecular machinery and functioning.The findings,published today in the journal Neuron, should make it easier for researchers to study how astrocytes relate to disease, or to develop drugs that aim...
Source: UCLA Newsroom: Health Sciences - July 13, 2017 Category: Universities & Medical Training Source Type: news
CathVision inks investment deal for electrophysiology system
Early-stage medical device company CathVision said today it inked a “multi-million venture investment” to support the development and marketing of its electrophysiology recording system designed for treating cardiac arrhythmia. The undisclosed investment came from Scandanavian-based VF Venture and Borean Innovation, Denmark-based CathVision said. “CathVision works in one of the fastest growing segments in medical technology. CathVision’s team has worked patiently and consistently with their product over a number of years, and we have followed the company for several years. I think CathVision represe...
Source: Mass Device - July 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular cathvision Source Type: news
Adverse Drug Event Causality Analysis (ADECA): a process for evaluating evidence and assigning drugs to risk categories for sudden death - Woosley RL, Romero K, Heise CW, Gallo T, Tate J, Woosley RD, Ward S.
Growing evidence indicates that many drugs have the ability to cause a potentially lethal cardiac arrhythmia, torsades de pointes (TdP). This necessitates the development of a compilation of drugs that have this potential toxicity. Such a list is helpful i... (Source: SafetyLit)
Source: SafetyLit - June 24, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Tenth year of data on cardiac arrhythmia treatment launched at European congress
(European Society of Cardiology) The tenth year of data on cardiac arrhythmia treatment is being launched at EHRA EUROPACE - CARDIOSTIM 2017. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 18, 2017 Category: International Medicine & Public Health Source Type: news
Medical News Today: Does the sound of airplanes raise blood pressure risk?
A new study investigates the effect of long-term exposure to aircraft noise on the risk of high blood pressure, cardiac arrhythmia, and stroke. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2017 Category: Consumer Health News Tags: Public Health Source Type: news
Lessons from Fire Prevention: Why We Can Head Off Disease Without Sacrificing Cure
This insightful and data-filled evidence-based article from the Boston University School of Public Health illustrates the work EMS can, and should, do to prevent disease where we cannot control curing it: Public health is concerned with creating a healthier world, preferably one where we prevent disease before it starts. This inevitably occasions grappling with our overwhelming investment in medicine and curative care, and arguing for a recalibration of our investment towards the social, economic, and cultural factors that promote health. We can educate people how to reduce their chances of suffering heart attacks, ...
Source: JEMS: Journal of Emergency Medical Services News - June 11, 2017 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT P Tags: Training News Source Type: news
Acute alcohol intoxication in an eight weeks old infant - Frenkel Rutenberg T, Benacun M.
INTRODUCTION: Alcohol intoxication in infants is a life-threatening condition which requires early diagnosis and treatment. It may lead to multi-system injury, including mental deterioration, respiratory depression, cardiac arrhythmia, metabolic disorders ... (Source: SafetyLit)
Source: SafetyLit - June 1, 2017 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Bathroom scales will inform about life threatening conditions
(Kaunas University of Technology) Weighing oneself has become one of the most common morning rituals. However, your weight is not the only message that can be delivered by your bathroom scales: the team of researchers at Kaunas University of Technology (KTU) Institute of Biomedical Engineering are developing the multifunctional scales, which can monitor your health and inform about potentially dangerous life conditions, such as arteriosclerosis or cardiac arrhythmia. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 16, 2017 Category: Biology Source Type: news
Arthur Moss Receives Heart Rhythm Society ’s Pioneer in Cardiac Pacing and EP Award
Arthur J. Moss, M.D., received the award for his dedication to understanding and treating electrical disturbances of the heart, including cardiac arrhythmias, sudden cardiac death, heart failure and Long QT syndrome. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - May 12, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Abbott wins CE Mark for new TactiCath ablation catheter
Abbott (NYSE:ABT) said today that the TactiCath sensor-enabled ablation catheter it bought along with St. Jude Medical (NYSE:STJ) this year won CE Mark approval in the European Union. The Chicago-area healthcare giant said the new TactiCath device can be integrated with another St. Jude product, the EnSite Precision heart mapping system it launched earlier this year. “The goal in developing the TactiCath contact force ablation catheter, sensor enabled, was to provide the most innovative solution for treating atrial fibrillation and lead the way in clinical outcomes for patients with cardiac arrhythmias &nda...
Source: Mass Device - May 9, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Catheters Regulatory/Compliance Wall Street Beat Abbott stjudemedical Source Type: news
Abbott wins CE Mark for Confirm Rx cardiac monitor
Abbott (NYSE:ABT) said today that its St. Jude Medical (NYSE:STJ) subsidiary won CE Mark approval in the European Union for the ConfirmRx insertable cardiac monitor, touting as the world’s 1st smartphone-compatible ICM. The continuous heart monitor is designed to work with St. Jude’s myMerlin mobile app to allow physicians to remotely follow patients and diagnose arrhythmias. Abbott said it’s on the market in 10 “select” countries in Europe, with a full release slated for the 2nd quarter. The FDA is also reviewing the device, the Chicago-area healthcare giant said. &l...
Source: Mass Device - May 8, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Patient Monitoring Regulatory/Compliance Abbott st-jude-medical Source Type: news
Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor
Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe. (Source: eHealth News EU)
Source: eHealth News EU - May 8, 2017 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news